STOCKS TELEGRAPH

Author: ST Staff

  • Auddia Inc. (AUUD) stock prices surged today, Here is why?

    The stock of Auddia Inc. (AUUD) gained today in the current market after the company announced that they are partnering with Bleav Podcast Network and Vodacast. The stock gained more than 6.25% to reach $2.02 at the time of this writing. At the end of the last trading session, the stock closed at $1.90. The average volume of the stock traded was around 547.15K.

    Reason for the AUUD stock gain

    Today the Auddia Inc. (AUUD) announced that they starting a partnership with Blieve Podcast Network and Vodacast.In this partnership, Bleav will select six podcasts and create digital content for every new episode. Also, the hosts will advertise the Vodacastapp in the podcast in each episode.

    After the news hit the market the investors were in joy because of the companies joining together with their innovative technologies which give them a competitive edge in the market.

    Auddia Inc. (AUUD)’s technology will be used by Blieve a podcasting network to create rich content in the podcasts that will create a unique experience for its podcast listeners.

    AUUD will go the extra mile to create some extra revenue for the podcasters by having its digital feed content being shown to a larger target audience. In November the company reported that 90% of its users interact with its digital feed content that has contributed to the increase of app download by more than 230% compared to last year. They are expecting that the fans will get an even richer experience engaging with the digital feeds.

    Effect on the rise of the stock

    This major partnership in the history of Auddia Inc. (AUUD) is significant and its results have been reflected in the pre-market today. Due to which the price of the stock is gaining extraordinarily. This partnership will play an important role in increasing the market share of the company and bringing more revenue and addressing a larger target audience.

    Conclusion

    Investors are interested in Auddia shares. The current situation is an ideal and attractive scenario for investors to invest in low-priced technology stock and wait for its growth in the future. This ideal situation might show that nothing can stop the stock from further gaining its value but no one is sure whether the stock will decline or not.

  • Energy Transfer LP (ET) stock declined in the Pre-market, Here is why?

    The stock of Energy Transfer LP (ET) slightly declined in the Pre-market after the company announced their pricing of a secondary public offering of common units. The stock was valued in the pre-market at $8.29 losing 0.84% from the previous day’s closing. At the end of the last trading session, the stock closed at $8.18. The average volume of the stock traded in the last trading session was around 18.01 million.

    The reason for the ET stock decline

    On 7th December 2021, Energy Transfer LP (ET) stock announced that they are starting the underwritten secondary public offering that consists of 86,956,522 common units. This represents the limited partner interests in Energy Transfer (ET). The selling unitholder is announced to be CenterPoint Midstream Energy, Inc. (which is a subsidiary of CenterPoint Energy, Inc.).

    Today on 8th December 2021 Energy Transfer LP (ET) stock announced the pricing of the lastly announced underwritten public offering. The price of the 86,956,522 common was set for the gross proceedings of $665 million. The deal is expected to settle on 10th December 2021.

    The representatives of the underwriters Citigroup, J.P. Morgan, and Morgan Stanley will be granted a 30-day option to purchase 13,043,478 additional common units in the offering by the Selling Unitholder. The company itself is not selling any of the common units and nor it intends to receive anything from the sale of the common units in the offering. The offering is totally dependent on the market and other factors, and there is no specific time announced that as to whether or when the offering will be completed.

    Effect on the stock

    After this announcement, the stock of the company slightly lost its value. The investors were seen to be quite reluctant in investing in the stock of Energy Transfer LP (ET). The stock of the company was doing well, when the company in the last week announced their completion of Acquisition of Enable Midstream. The Combined operations were announced to be forecasted to generate an annual cost reduction of more than $100 million. Due to which the investors were highly interested in its future profitability.

    Conclusion

    The trend of the stock will be decided after any major development in the offering. The offer is expected to settle on 10th December 2021, till then the trend of the stock could remain certain.

  • Siyata Mobile Inc. (SYTA) stock gained today, Here is why?

    The stock of Siyata Mobile Inc. (SYTA) gained in the current market after the company announced a $1.3 million deal in the last few days. The stock gained more than 128.24% reaching $6.30 per share. At the end of the previous trading session, the stock closed at$2.76. The average volume of the stock traded was around 6.38 million.

    The reasons for the SYTA stock gain

    On 2nd December 2021, the company announced in a press release that they have received an initial order for SD7 Ruggedized Device from customers in the United States, Europe, the Middle East, and Africa. The total value of the combined order is approx. $0.55 million.

    The comparatively low cost of the SD7 device and its wide range of functionality makes it an exact need and affordable option for both enterprise customers and first responders units.

    The ruggedized device is Push-To-Talk (PTT) and easy to use. It has a small monochrome screen of 2 inches, a key for PTT, SOS, and Volume. With all these basic features it is Wi-Fi, Bluetooth and LTE enabled. This all comes with an android operating system to manage its functions. The device is rugged giving it drop protection and is resistant to water and dust. Its battery is suited for all kinds of environments having no effect on its performance.

    Today’s news was followed by major development in the order of $500,000 from Europe, the Middle East, and Africa after the company recently unveiled VK7. The company recently introduced their vehicle kit or VK7 on 29 November 2021 which is made to use with the SD7 device.

    The total value of the new orders is $1.3 million. That includes the orders of SD7 rugged device, vehicle kit or VK7, and other units, devices, and accessories.

    Effect on SYTA stock gain

    The investors were seen to be responding positively to the major development in the sales of the company. The VK7 is the first of its kind device whose patent is still pending. The device is supposed to be used along with the SD7. With this technology advancement, the investors are assuming that the company is expecting to receive more orders in the future. That is why the stock of Siyata Mobile Inc. (SYTA) was popular among investors today in the Pre-market.

    Conclusion

    The new technology is giving a competitive edge to the company in the relevant industry due to which the company can expect new orders in the future. This could give a boost to its revenue for the upcoming time period.

  • Jumia Technologies AG (JMIA) stock gained in the pre-market, Here is why?

    Jumia Technologies AG (JMIA) slightly gained in the pre-market today after the company announced the results of their Black Friday campaign of 2021. The stock was traded at $12.23 in the pre-market gaining more than 10.48% from the previously closed value. At the end of the last trading session, the stock closed at $10.76. The average volume of the stock traded in the last trading session was around 5.10 million.

    Results of the Black Friday Campaign 2021

    As of November 5-November 30 2021, the company witnessed its largest-ever Black Friday Campaign that reached a GMV of approximately $150 million in just 25 days. If we compare it with the last year this is an increase of more than 30% in a single year. The orders company recorded were around 4.3 million in total. This is an increase of 39% in the orders by the customers.

    JMIA claims to be a pioneer in introducing the Black Friday Sales concept in Africa in the year 2012. Now their campaign is the most awaited Black Friday campaign since 2012. The most important factor was the increase in the number of new visitors on their platform. This year 40 million new visitors came to their e-commerce platform. This will have a huge impact on grabbing new market share in the future which will increase the profitability of the company.

    The Black Friday Sales campaign saw high seller participation with over 46,000 Active Sellers during the campaign compared to 41,500 in the last year. During this year’s Black Friday Sales, their top 20 physical goods sellers increased their GMV by three times on average. Their restaurant partners were a vital and important part of the success of their Black Friday Sales Campaign of 2021, they offered a variety of discounts and deals on the exclusive meal. The GMV of the food delivery category almost doubled as compared to the last year. The average GMV growth of the top 20 restaurants during the 2021 campaign experienced an increase of 167% as compared to 2020.

    Effect on the Jumia Technologies AG (JMIA) stock

    After the announcement of the report and seeing the success rate of their Black Friday Campaign of 2021, the investors were seen to be interested in investing in JMIA stock. The stock gained more than 10% in value in the pre-market as soon as the news hit the market.

    Conclusion

    The stock of Jumia Technologies AG (JMIA) is gaining after the announcement of the result of their Black Friday campaign. The important factor in the news was its introduction of the platform to new 40 million customers, which is a huge number. If they target them well in the future it could bring a great number of revenue for the company.

  • Meten Holding Group Ltd. (METX) gained in the Pre-market, Here is why?

    Meten Holding Group Ltd. (METX) gained in the Pre-market, Here is why?

    The stock of Meten Holding Group Ltd. (METX) gained value in the Pre-market today. The stock was valued at $0.3106 gaining 9.75% from the previously closed value. At the end of the last trading session, the stock closed at $0.26. The average volume of the stock traded in the trading session was around 170.70 million.

    Reason for the METX stock gain:

    The reason for the METX stock gain is not related to a recent development by the company. But 2 weeks ago the company announced their financial results for the 3rd quarter of 2021. The company announced that due to the covid-19 pandemic situation they moving forward to close their offline educational institutes except for 1 or 2 centers. The fixed cost of the company will be greatly reduced by it. Due to this, the company is expected to increase its profitability in the next quarter.

    They also said that being an educational giant in the industry they are looking forward to focusing on Metaverse. They are looking forward to finding out new opportunities that are related to the Metaverse. The company said that they are moving forward to use their offline centers as a career planning and building professional skills of the individuals to train them with the required set of skills related to the Metaverse.

    The Company said that it will also explore the emerging industry of blockchain and cryptocurrency and is trying to explore overseas opportunities. During the last month, they have formed a strategic and business partnership with AGM Group Holdings. The company is seeking opportunities in mine construction, mining, and manufacturing, and mining machines sales. They are looking forward to joining a cryptocurrency fund as a limited partner to further expand their business vision and seek opportunities to invest in companies with extraordinary potentials.

    Effect on the stock rise:

    The investors are seen to trust the company in their vision and were seen to be interested in buying its stock. Due to this, the stock of the company increased almost 10% in the Pre-market. The company is moving to establish its new business strategies to generate more income streams and diversify its investments to increase profitability and expand its business. This could benefit the investors in the future in terms of capital gain.

    Conclusion:

    The rise of the new coronavirus variant is a threat for every industry. Any positive or negative development in the situation in terms of the variant spreading could affect the stock value and market as a whole.

  • Sorrento Therapeutics, Inc. (SRNE) stock gained in Pre-market, Here is why?

    Sorrento Therapeutics, Inc. (SRNE) stock gained in Pre-market, Here is why?

    The stock of Sorrento Therapeutics, Inc. (SRNE) gained value after the company announced that a series of publications of Main Protease of Novel SARS-Cov-2 inhibitors which could be a potential treatment for the Covid-19 patients infected with SARS=CoV-2 variants of all concern including Omicron. Due to which the stock gained a value of more than 1.72% in the Pre-market to reach $5.03. At the end of the last trading session, the stock closed at $5.51. The average volume of the stock tared in the trading session was around 5.02 million.

    Reason for the SRNE stock gain

    As soon as the news of Sorrento Therapeutics hit the market the stock gained significantly and was trusted by the investors to invest in its stock forecasting its growth in the near future. The company announced in a series of publications that Main Protease of Novel SARS-Cov-2 inhibitors could be a potential treatment for the Covid-19 patients infected with SARS=CoV-2 variants of all concerns including Omicron.

    Amongst the series one of the novel MPro inhibitors, MPI8, inhibits both MPro and cathepsin L, an important viral entry enzyme. This enzyme has high potency and selectivity. The different Analogs of the series have been evaluated by the company to form an oral anti-viral COVID drug for the treatment of patients that are infected with all the current or emerging variants of the SARS-Cov-2 which includes the deadly Omicron. In the series of different analogues a promising and potential candidate of unique features that are distinguished from SARS-CoV-2 MPro inhibitors published by others has been systematically evaluated and moved forward to the final stage of the pre-clinical phase.

    Evidence in the experiments

    The evidence shows in the experiments that the certain host proteases SARS-CoV-2 spike protein for viral packaging, interactions with ACE2, and viral entry into the host. It consists of 2 serine proteases one is furin and transmembrane protease serine 2 (TMPRSS2) and the other is cysteine protease cathepsin L. both the Small molecule medications that inhibit furin, transmembrane protease serine 2 (TMPRSS2), and cathepsin L have shown effective results in stopping the replication of SARS-CoV-2.

    The Sorrento Therapeutics in partnership with Prof. Liu’s Lab at Texas A&M University is moving forward to evaluate the development of an oral anti-viral COVID drug.

    Effects of the major development on its stock and conclusion

    The investors seemed to take a high interest in SRNE stock. If the company succeeds to developed an anti-viral drug for Covid-19 and all of its current and emerging variants this will be a major breakthrough for it.

  • Big Lots, Inc. (BIG) stock increasing today, Here is why?

    Big Lots, Inc. (BIG) stock increasing today, Here is why?

    The stock of Big Lots, Inc. (BIG) slightly inclined today after the company announced its 3rd quarter results today. The stock gained around 4.59% value to reach $45.62 in the current market. At the end of the previous trading session, the stock closed at $42.58. The average volume of the stock traded in the regular trading session was around 630.55K.

    Highlights of 3rd quarter results:

    • Sales in the 3rd quarter were reported to be $1.336 billion. This is a decrease of 3.1% in the quarterly revenue of the same quarter of 2020. Last year in the 3rd quarter the revenue was $1.378 billion.
    • The net loss was reported to be $4.3 million. In the same quarter of last year, the net income was $29.9 million.
    • As of 30th September 2021, the BIG stock had cash and cash equivalents of around $71 million with no long-term debt. In the same quarter of the last year, the company had cash and cash equivalent of $548 million and long-term debt of $39 million.

    Impact of the financial results on Big Lots, Inc. (BIG):

    When the company announced its quarterly results, the investors were seen to be quite reluctant in investing its shares. The company’s loss was not that much significant but it lost more than $509 million in cash and cash equivalent. They have been left with approx. $39 million as compared to 3 quarters before when they had $548 million in cash and cash equivalents. The company did not mention why they lost so much cash in a span of a limited time period. There are no other major investments or ventures which could be linked to its cash bleeding.

    The company’s loss in sales could be linked to its existing supply chain issue. They said the supply chain issue will be there in near future and they are in constant touch with their transport and manufacturing partners.

    Conclusion:

    The company forecasts that the sales are expected to increase in the fourth quarter. They are expecting that the earning per share should increase between $2.05 and $2.20 due to the expected positive sales increase as compared to the current situation. The new store openings would contribute to the revenue of the company.

  • Novavax, Inc. (NVAX) stock gained in the Pre-market, Here is why?

    Novavax, Inc. (NVAX) stock gained in the Pre-market, Here is why?

    The stock of Novavax, Inc. (NVAX) gained value in the pre-market after the company announced that they will start preparing a vaccine that would be specifically designed for Omicron coronavirus. After the news hit the market, the stock gained more than 6.81% to reach $173.00. At the end of the previous trading session, the stock closed at $161.97.

    Novavax is developing a vaccine for Omicron Variant:

    On 2nd December 2021, Novavax, Inc. (NVAX) announced in a press release that they will be evaluating its vaccine against the Omicron variant in the first place as they did for the other variants of the novel corona virus-like Alpha, Beta, and Delta variant. The company also announced that other than relying on the evaluation data of the impact of the current vaccine on the Omicron variant, they have also started the development of a vaccine that is specific to the Omicron variant.

    Impact of the vaccine for a new variant on NVAX stock:

    Although Novavax, Inc. (NVAX) is already one year late in the deployment of their current vaccine due to the production issues, they have to yet deploy their original coronavirus vaccine in the developed markets and send the data to FDA which is likely to be done at the end of 2021. The investors should be positive about the company’s performance and its stock value because as the new variant of the virus is on rising and have already reached 24 countries, there is a demand for the booster shot and its already developed vaccine could be a potential candidate in becoming a choice as a booster vaccine. That will increase its profitability and will be able to reach the already saturated markets.

    Secondly, they have stated that in the upcoming weeks they will be ready to have a vaccine shot that will target the omicron virus because they have already started their development on updating the vaccine that is supposed to target the recent variant. But should not expect too much from the company in such a short span of time because they have already struggled in manufacturing the vaccine due to production problems.

    Conclusion:

    The upcoming weeks will be crucial for the stock of Novavax. If they succeed in getting orders for their current vaccines as a booster shot it will increase the revenue for the company. But the company is also stressing developing a vaccine for the Omicron variant.

  • Farmmi, Inc. (FAMI) stock was seen to gain value today, Here is why?

    Farmmi, Inc. (FAMI) stock was seen to gain value today, Here is why?

    The stock of Farmmi, Inc. (FAMI) gained value today. The stock gained around 8.06% in the current-market trading session to reach $0.25. At the end of the previous trading session, the stock closed at $0.23. The average volume of the stock traded in the trading session was around 80 million.

    Reason for the FAMI stock gain:

    The stock of Farmmi, Inc. (FAMI) slightly gained in the current market. The change was not much significant but the investors took great interest in the stock after the company announced that NASDAQ confirms the company’s additional 180 day period for the submission under its least bid price requirement till 30th of May, 2022. The requirement for the compliance of bid price with NASDAQ is that the company’s common stock closing bid price should be at least $1.00 or greater than it for 10 consecutive working days or more than that by the time of 30th May 2022.

    Although the valuation of the stock is far less than it should be, the company is expected to boost North American sales which will have a significant effect on its profitability. The company announced in the mid of November that their subsidiary company Zhejiang Farmmi Biotechnology have won another new product order. The customer will export the dried black fungus to Canada.

    Farmmi, Inc. (FAMI) diversifying its business:

    The company is diversifying its product line and portfolio in the future and one can’t just limit it to the fungus products. Their major development in the recent past is that they expanded into the health sector and acquired the 1% equity in Shanghai JiaodaOnlly. This is the largest elderly-care and rehabilitation institute in China. The JiaodaOnlly revenue in the fiscal year of 2020 was around $52 million or 333 million yuan.

    Conclusion:

    The low valuation of the company doesn’t mean that it’s not worthy of investing. The company is expanding into different markets in the future and introducing its product line there. They are also investing in different industries to diversify their business and increase its profitably. Farmmi, Inc. (FAMI) is expected to perform well if its profitability increases in the future and investors can invest at the right time.

  • The stock of NewAge, Inc. (NBEV) gained today, Here is why?

    The stock of NewAge, Inc. (NBEV) stock gained 3.27% in the current market to reach $1.17. At the end of the last trading session, the stock closed at $1.20. The one-year range of the stock was between $1.13 and $4.44, this is a loss of more than 65% value in its stock in the last trading session, the average volume of the stock traded was around 1.93 million.

    The reasons for the NBEV stock uncertainty:

    In the month of November, NBEV announced its 3rd quarter results and new development in the discovery of new anti-aging formula. When the company announced its new formula the stock of the company increased for a couple of days and then declined the day after.

    NBEV announced in the mid of November that they have discovered a new formula that fights against the effect of aging and filed for a patent that specific formula to protect its uniqueness. This formula is found to be effective in the support of heart health and anti-aging. This new discovery will be able to help in the formation of a medicine that will help to extra-ordinarily increase the natural secretion of an element called human growth hormone produced by the anterior pituitary gland.

    Heart health decreases with aging. This product by the Colorado origin organic and healthy products manufacturer also said that the new product will also be effective in improving cardiovascular health.

    Another reason which helped the stock to surge for a short span of time was the financial and operational results of its 3rd quarter report. Following are the highlights of their third-quarter result.

    Highlights of 3rd quarter:

    • The revenue of NBEV was $99.55 million in the 3rd quarter of 2021. This is a 58.73% increase in revenue as compared to the 3rd quarter of 2020. Last year in the same quarter the revenue was $62.72.
    • The net loss was reduced by more than 80% to – ($2.70 million) in the 3rd quarter of 2021. The net loss in the same quarter of 2020 was reported to be – ($14.13 million).
    • The gross margin was 66.3% of the net revenue in the 3rd quarter of 2021 as compared to 59.8% in the same quarter of 2020.
    • The company’s cash and cash equivalent as of 30th September 2021 was reported to be $46.83. This is an increase of 74.18% as compared to cash in hand in the same quarter of last year which was $26.89 million.

    Conclusion:

    The financials of NBEV showed a significant increase in the numbers and if the company remains consistent in delivering at the same pace, the profitability will increase with the inclusion of the new products. This will increase the trust of the investors in its stock to invest more in the expectation of a capital and dividend gain.